文献速递类风湿关节炎

抗瓜氨酸化蛋白抗体谱可预测开始生物制剂治疗类风湿关节炎患者的疾病活动度变化

Anti-citrullinated protein antibody profiles predict changes in disease activity in patients with rheumatoid arthritis initiating biologics.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

研究纳入前瞻性非随机观察性RA队列中1092例开始生物制剂治疗的患者,检测25种瓜氨酸化肽段ACPA,用主成分分析(PCA)评估其与6个月EULAR治疗反应的关系。结果显示仅PC1和PC2最高四分位与治疗反应相关,且ACPA谱与商业抗CCP3抗体水平相比关联更强,但PCA仍需进一步改进以有效区分不同生物制剂。

要点

  • PC1最高四分位与治疗反应相关(OR 1.76;95%CI 1.22, 2.53)。
  • PC2最高四分位与治疗反应相关(OR 1.74;95%CI 1.23, 2.46)。
  • ACPA谱与生物制剂治疗反应的关联似乎强于商业抗CCP3抗体水平。

核心结论

  • 扩展的ACPA谱似乎比商业可用的抗CCP3抗体水平与RA生物制剂治疗反应的关联更强。
  • 需要进一步改进PCA才能有效区分可用于RA治疗的不同生物制剂。

研究设计与样本

  • 研究为前瞻性、非随机、观察性RA队列中的子研究。
  • 纳入1092例参与者,平均年龄57(13)岁,79%为女性。
  • 治疗组包括未使用过生物制剂者起始抗TNF、曾暴露于生物制剂者起始非TNF、未使用过生物制剂者起始阿巴西普。
  • 采用入库时血清检测25种瓜氨酸化肽段的ACPA,并进行主成分分析(PCA)。
  • 使用校正序数回归模型分析主成分得分(按四分位)和抗CCP3抗体(≤15、16-250或>250 U/ml)与6个月EULAR治疗反应(良好/中等/无)的关联。

主要发现

  • 6个月时68.5%达到中等/良好EULAR反应。
  • 三个主成分累计解释ACPA值变异的70%。
  • 在包含三个主成分和抗CCP3抗体类别的模型中,仅PC1和PC2与治疗反应相关。
  • PC1最高四分位与治疗反应相关(OR 1.76;95%CI 1.22, 2.53),PC2最高四分位与治疗反应相关(OR 1.74;95%CI 1.23, 2.46),均为多变量校正后结果。
  • 主成分与治疗组在EULAR反应间无交互作用证据(交互作用P值>0.1)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步改进PCA才能有效区分可用于RA治疗的不同生物制剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine whether an expanded antigen-specific ACPA profile predicts changes in disease activity in patients with RA initiating biologics. METHODS: The study included participants from a prospective, non-randomized, observational RA cohort. For this sub-study, treatment groups of interest included biologic-naïve initiating anti-TNF, biologic-exposed initiating non-TNF, and biologic-naïve initiating abatacept. ACPAs to 25 citrullinated peptides were measured using banked enrolment serum. Principal component analysis (PCA) was performed and associations of resulting principal component (PC) scores (in quartiles) and anti-CCP3 antibody (≤15, 16-250 or >250 U/ml) with EULAR (good/moderate/none) treatment response at 6 months were examined using adjusted ordinal regression models. RESULTS: Participants (n = 1092) had a mean age of 57 (13) years and 79% were women. At 6 months, 68.5% achieved a moderate/good EULAR response. There were three PCs that cumulatively explained 70% of variation in ACPA values. In models including the three components and anti-CCP3 antibody category, only PC1 and PC2 were associated with treatment response. The highest quartile for PC1 (odds ratio [OR] 1.76; 95% CI: 1.22, 2.53) and for PC2 (OR 1.74; 95% CI: 1.23, 2.46) were associated with treatment response after multivariable adjustment. There was no evidence of interaction between PCs and treatment group in EULAR responses (P-value for interaction >0.1). CONCLUSION: An expanded ACPA profile appears to be more strongly associated with biologic treatment response in RA than commercially available anti-CCP3 antibody levels. However, further enhancements to PCA will be needed to effectively prioritize between different biologics available for the treatment of RA.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Aripova N, Kremer JM, Pappas DA, et al. Anti-citrullinated protein antibody profiles predict changes in disease activity in patients with rheumatoid arthritis initiating biologics. Rheumatology (Oxford). 2024. PMID: 37252826. doi:10.1093/rheumatology/kead260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。